We have identified amino acid residues within the evolutionarily conserved 1 domain of the o~-chain (CD11a) of the leukocyte integrin leukocyte function-associated antigen (LFA) 1 that are critical for intercellular adhesion molecule (ICAM) 3 (CD50) binding. ICAM-3, a ligand of LFA-1, is thought to mediate intercellular adhesion essential for the initiation of immune responses. Using a panel of human/murine I domain chimeras and point mutants, we observed that the Ile-Lys-Gly-Asn motif, located in the NH2-terminal part of the CDlla I domain, is required for ICAM-3 but not ICAM-1 binding. These findings demonstrate that the I domain of CD1 la contains distinct functional subdomains for ligand specific binding. An aspartic acid located at position 137, which is essential to ICAM-1/LFA-1 interactions (Edwards, C.P., M. Champe, T. Gonzalez, M.E. Wessinger, S.A. Spencer, L.G. Presta, P.W. Berman, and S.C. Bodary. 1995.J. Biol. Chem. 270:12635-12640), was also critical for ICAM-3 binding, whereas Ser at position 139 did not effect ICAM-1 or ICAM-3 binding. A synthetic peptide containing the Ile-Lys-Gly-Asn motif inhibited ICAM-3-dependent adhesion and proliferation of T cells at micromolar concentrations, suggesting that this peptide interferes with immune recognition. These observations underscore the importance oflCAM-3 in leukocyte function, and may lead to development of a new category of immunosuppressive agents.
T he integrin leukocyte function-associated antigen (LFA) 1 (CDlla/CD18) is a leukocyte-specific adhesion receptor that modulates adhesive interactions and signaling functions in the immune system (1-3). LFA-1 mediates cell--cell adhesion upon binding to its ligands intercellular adhesion molecule (ICAM) 1 (CD54), ICAM-2 (CD102), or ICAM-3 (CD50) (4--8) . Several studies (9--13) have demonstrated that activation of LFA-1 is required for adhesion, and that this can be induced in vitro by engagement of the TCtL-CD3 complex. Altematively, LFA-1 can be activated by exposure to divalent cations (Mn 2+) or treatment with activating mAbs to CDlla or CD18.
Although LFA-1 binding sites have been located in the NH2-terminal Ig domains oflCAM-1 and -3 (14) (15) (16) , and otEI37) and are homologous to the type A domains ofvon Willebrand factor, cartilage matrix-binding protein, and complement factor B (17, 18) , are essential to ligand binding (19) (20) (21) (22) (23) . The observations that most blocking mAbs to CD1 la map to the I domain (22) (23) (24) and that recombinant I domains both inhibit integrin-mediated adhesion and possess ligand-binding activity (19) (20) (21) underscore the role of the I domain in ligand binding.
In this study a panel of human/murine CD1 la I domain mutants were used to identify amino acids that were essential for the binding of LFA-1 to ICAM-3. We observed that residues located in the NH2-terminal portion of the I domain ofCD1 la are critical for ICAM-3 binding, but not for ICAM-1 binding.
Materials and Methods
Antibodies. Function-blocking mAbs directed against human CDlla NKI-L15 (11), human CD18 (MHM23) (25) , and murine CD1 la (M17) (26) were used. mAbs R.ek-I (anti-ICAM-1; CD54) (6) and AZN-IC3.1 (anti-lCAM-3; CD50) (Binnerts, M.E., S.J. van Vliet, Y. van Kooyk, and C.G. Figdor, manuscript in preparation) were used to inhibit LFA-1/ICAM-1 or LFA-1/ ICAM-3 interactions, respectively. For cell adhesion studies, the activating antibody KIM185, directed against CD18 (12), was used. The mAb T3b, directed against CD3 (27) , was used for T cell costimulation assays.
Generation of CD 1 l a I Domain Mutants. The generation of human/mouse (H/M) chimeras, the I domain point mutants, and mu3, has been described previously (24, 28) . mu I and mu2 were generated by overlap extension PCIL. Briefly, using full-length human CD11a cDNA (piLK LFAotm) and mu3 cDNA as templates, the NH 2-and COOH-terminal halves of the mul and mu2 1 domains were generated by PCIL (mul: for residues 125-234, mu3 was used, and for residues 235-308, pR.K LFAcxm was used; mu2: for residues 125-234, pRK LFA~m was used, and for residues 235-308, mu3 was used.) The Bglll at residue 297 was removed from the mul I domain. The two halves of mul and mu2 were joined by overlapping extension PCIL and cloned into the CDlla at the appropriate I domain restriction sites (Narl, BglIl: mul; Narl, PflMl: mu2).
Expression of CD 1 la I Domain Mutants in 293 Cells. Mutated CD1 la and wild-type CDI8 cDNAs were cloned into the ILK 5 and ILK 7 expression plasmids .and transfected into the 293 human kidney adenocarcinoma cell line using a standard calcium phosphate coprecipitation method (29) . Transfection e~ciencies ranged from 20 to 70%. After 3 d, transfectants were harvested by EDTA (5 rnM) treatment and were assayed for adhesion to ICAM-1 and ICAM-3. Staining of the transfectants with various anti-LFA-I mAbs revealed that the mutations did not affect the overall conformation of the LFA-I heterodimer (28) (data not shown).
Adhesion to ICAM-I and ICAM-3. ICAM-1 and ICAM-3 fusion proteins consisting of the five domains oflCAM-1 or ICAM-3 fused to a human lgG1 Fc fragment (ICAM-1Fc, ICAM-3Fc, respectively) were isolated from supernatants of L cell cultures stably transfected with plCAM-IFc and plCAM-3Fc, respectively (7, 16) . Culture supematant was purified by protein A column affinity chromatography and eluted with 3.5 M MgCI 2 and 10% glycerol. 96-well plates (Maxisorb; Nunc, ILoskilde, Denmark) were precoated with 4 Ixg/ml goat anti-human Fc (Jackson ImmunoiLesearch Laboratories, Inc., West Grove, PA) for 2 h at 37~ and blocked with 1% BSA (Boehringer Mannheim, Mannhelm, Germany) (1 h at room temperature). ICAM-IFc or ICAM-3Fc proteins were coated overnight at 4~ or at 37~ for 2 h, at a concentration of 200 ng/well. Transfected 293 cells (200,000 cells/well) were added in adhesion buffer (0.14 M NaCI, 0.02 M Hepes, 0.2% glucose, 1 mM MgCI2, and 1 mM CaCI2), with the anti--CD18-activating mAb KIMI85 (12) and allowed to adhere for 1.5 h at 37~ Nonadherent cells were removed by washing three times with PBS, and cell attachment was measured using the PNAG (P-nitrophenyl-N-acetyl-13-D-glucosaminide) method of Landegren (30) . The mean OD405 of triplicate wells was determined and corrected for the expression levels ofCD1 la/CD18 on the distinct transfectants. For comparison 50,000 cells gave an average OD of 1. For adhesion of the human T cell line HSB (obtained from American Type Culture Collection, ILockville, MD), cells (40,000/well) were labeled with StCr for 45 n'fin at 37~ Cells were incubated with different concentrations of synthetic peptides followed by activation with KIMI85. Subsequendy, cells were incubated on ICAM-1Fc-or ICAM-3Fc---coated plates for 30 rain at 37~ in the presence of peptides and KIM185. Nonadherent cells were removed by three washes with adhesion buffer, adhering cells were lysed with 1% Triton X-100, and radioactivity was quantified. Results are expressed a.s the mean percentage of adhesion of triplicate wells.
Proliferation Assay. 96-well plates were coated with suboptimal concentrations ofanti-CD3 antibodies (T3b, 10 ng/well, I h at 37~ followed by goat anti-human Fc (400 ng/well, 1 h at 37~ 1% BSA (100 I~l/well, 30 min at 37~C) and ICAM-1Fc or ICAM-3Fc proteins (100 ng/well, 1 h at 37~
ILestmg PBL obtained by centrifugal elutriation from normal donors as described previously (31) were added (100,000 cells/well) and cultured for 3 d. On day 3, cells were pulsed for 16 h with [3H]thymidine (1.52 TBq/mmol, 0.5 ~Ci/well; Amersham Corp., Arlington Heights, 1L), and uptake was quantified to measure ICAM-1-or ICAM-3-dependent proliferation. To determine whether induced proliferation was LFA-1 and ICAM-I specific, ceils were cultured in the presence of function-blocking antibodies at a concentration of 10 Ixg/rnl.
Results and Discussion
Despite the high sequence homology between human and mouse LFA-1, murine LFA-1 does not bind human ICAM-1 (32) . Exploiting this species specificity, we determined that substitution of murine I domain sequences into human CDlla abolished the ability of LFA-1 to bind ICAM-1 (28) . In this study, we adopted a similar strategy to determine the role of I domain sequences in LFA-1/ ICAM-3 interactions. A panel of H/M CDlla I domain mutants was used, some of which correspond to epitopes recognized by CD1 la blocking mAbs (24) , to identify amino acids that were essential for the binding of LFA-1 to ICAM-3 ( Fig. 1) . The capacity of 293 cells transfected with cDNAs encoding chimeric CD1 la and human CD18 to bind purified human ICAM-1Fc and ICAM-3Fc is shown in Fig. 2 A. Wild-type human CDlla/CD18 transfectants bound both ICAM-1 and ICAM-3. As had been previously shown with ICAM-1 (28), the mu3 chimera (which contains the complete murine I domain) did not bind human ICAM-3. FACS | analysis, using the M17, NKI-L16, and MHM23 rnAbs (11, 25, 26) , showed that the mu3 chimera contains the expected murine I domain epitopes as well as human CD1 la and CD18 epitopes, suggesting that this heterodimer was correctly folded (28) . Thus it appeared that the I domain of murine LFA-1 lacked the binding site(s) for ICAM-3 as well as ICAM-1. We also observed that mul (which contains the NH2-terminal portion of the murine I domain) bound ICAM-1 but not ICAM-3, whereas mu2 (which contains the COOH-terminal portion of the murine I domain) bound to both ICAM-1 and ICAM-3. We conclude that the NH2-terminal portion of the human I domain contains residues critical to ICAM-3 binding, and that ICAM-I and 1CAM-3 bind to distinct sites within the I domain of LFA-1. Precise mapping of residues involved in ICAM-1 binding is in progress.
To precisely locate the ICAM-3 binding site in the NH2-terminal portion of the I domain, we tested the ability of seven H/M chimeras to bind ICAM-3. (Fig. 2 ) The overall conformation of these H/M LFA-I chimeras was intact and did not affect ICAM-1 binding (24, 28) . Of all H/M chimeras tested, only H/M53, in which the human Ile-126 and Asn-129 were replaced with murine residues Met and Lys, respectively, completely abrogated adhesion to ICAM-3 (Fig. 2 B) . In contrast, the adhesion of this mutant to a wide range of concentrations of ICAM-1 showed identical binding as that of wild-type CD11a (data not shown). This indicates that the loss of binding of H/M53 to ICAM-3 was not due to the low afl]nity of ICAM-3, compared with ICAM-1, for LFA-1. Point mutations of Ile-126 and Asn-129 revealed that only the replacement of Asn with Lys at position 129 dramatically reduced the adhesion to ICAM-3. When Lys-127 and Gly-128, which are conserved between the human and mouse, were mutated to Ala, only the Lys-127 mutation led to reduced binding to ICAM-3. These data demonstrate that residues critical for ICAM-3 binding are located in the NH2-terminal portion of the I domain ofCD1 la within the Ile-Lys-Gly-Asn motif at positions 126-129, and that Lys-127 and Asn-129 are critical to ICAM-3 binding (Fig. 2 C) .
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It is interesting to note that the Ile-Lys-Gly-Asn sequence was previously found to be critical for the binding of several mAbs to murine and human CD11a that block binding to ICAM-1 (24) . Although subsequent studies (28) demonstrated that these residues were not directly involved in ICAM-1 binding, the fact that an immediately adjacent sequence (residues 130-143) was highly conserved among the CD11 integrin I domains, as well as homologous domains van Kooyk et al. Brief Definitive Report Fig. 2 D) . In contrast, mutation of Ser-139 to Ala did not profoundly effect LFA-1 binding to ICAM-1 or ICAM-3, suggesting that Ser-139 of CD 1 la may not be involved in cation coordination. Since the residues corresponding to the Ile-Lys-Gly-Asn motif were absent from the Mac-1 I domain fragment used for the x-ray diffraction study (34) , and since Mac-1 lacks a homologous sequence, it will be of interest to determine the structure and proximity of this motif to the CDlla cation binding site. To obtain further insight into the role of the Ile-LysGly-Asn-126 to 129 and the Asp-137 sequences in binding oflCAM-3 to LFA-1, a series ofpeptides that spanned this region of CDlla were synthesized (Fig. 3) . Interestingly, we observed that low concentrations of one peptide efficiently inhibited the ability of the LFA-l-expressing T cell clone HSB to bind to ICAM-3, but not to ICAM-1 (pep- +pel~de-3-0 dicate that the sequences surrounding this motif are important for the inhibitory effect ofpeptide 2. Since ICAM-3 is thought to play a role in the initiation of the immune response, we investigated whether the Ile-Lys-Gly-Asn-containing peptides also affected immune function. We assayed whether the peptides would inhibit either the ICAM-1 or ICAM-3/CD3-induced costimulation of resting PBL proliferation (35) . As illustrated in Fig. 4 , peptide 2 inhibited ICAM-3--induced proliferation, but not ICAM-l-induced proliferation. Peptides 1 and 3 were inactive. The inhibitory activity of the peptides is likely to result from binding of the peptide to residues of ICAM-3 that are involved in LFA-1 binding. This is currently under investigation.
Comparison of the sequence homology of the I domains of the other CD18 integrins indicated that the Ile-Lys-GlyAsn motif is unique to CDlla, suggesting that LFA-1 contains a unique binding site for ICAM-3. Indeed, no studies have reported Mac-l-or p150/95-mediated binding to ICAM-3 3000 Figure 4 . Inhibition of ICAM-3 costimulation of PBL with I domain peptides. Resting PBL (100,000 cells/well) were cultured in the presence of the synthetic peptides (100 I.Lg/ml; depicted in Fig. 3 ) on plates coated with ICAM-1Fc (white bars) and ICAM3Fc (black bars) (100 ng/weU) along with suboptimal concentrations ofanti-CD3 mAb (1 ng/well) for 3 d at 37~ One experiment out of three, in which triplicate determinations were carried out, is shown.
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ICAM-3. It will be interesting to know whether the recently described fourth member of the CD18 integrins CD11d/CD18 contains the Ile-Lys-Gly-Asn sequence in the I domain, since there is evidence that this heterodimer binds to ICAM-3 with high affinity (36) .
Collectively, these findings demonstrate for the first time that the I domain of CDlla contains distinct functional subdomains for ligand-specific binding: a conserved Asp-137 residue important for binding of ICAM-1 and -3, an IleLys-Gly-Asn domain important for binding of ICAM-3, and distinct, yet-to-be-defined residues important for binding of ICAM-1 (37). Our finding that low concentrations of I domain peptides significantly inhibit ICAM-3-dependent immune function, without affecting ICAM-l-dependent function, may direct the development of a new class of antiinflammatory/immunosuppressive agents for the treatment of diseases such as arthritis or graft rejection after organ transplantation.
